Member of the Legislative Council Natasha Maclaren-Jones today  welcomed the NSW Government’s announcement that a Memorandum of Understanding (MOU) has been signed with GW Pharmaceuticals (GW) to progress a major new research program for cannabis-based medicines in children with severe, drug resistant paediatric epilepsy.

Mrs Maclaren-Jones said many children are suffering and this announcement provides hope for families.

“This is a Government showing incredible progress, NSW is the first state in Australia to provide legal and safe access to cannabis-based medicines for children suffering from drug resistant epilepsy,” Mrs Maclaren-Jones said.

The MOU will facilitate:

  • A world first, phase 2 clinical trial in children for GW’s novel product containing the cannabinoid cannibidivarin (CBDV)
  • A compassionate access scheme for EpidiolexÒ, GW’s product containing cannabidiol (CBD) which is currently in late stage trials in paediatric epilepsy in the United States
  • Provision for NSW to host additional Phase 3 clinical trials of EpidiolexÒ in children with treatment-resistant epilepsy
  • A phase 4 clinical trial of EpidiolexÒ based on phase 3 studies


The MOU, between the NSW Government and GW Pharmaceuticals, comes as part of the NSW Government’s $21 million commitment to support clinical trials and establish the NSW Centre for Medicinal Cannabis Research and Innovation.

More information about medicinal cannabis in NSW is available at

Specific information regarding trials email or call the Cannabis Trials Help Line on 1800 217 257.